Trade This High Risk / High Reward Stock for a 31% to 59% Potential Upside

We recently started a series called “Penny Stock of the Day”. These ideas are geared towards traders with an extremely high risk appetite.

Our Penny Stock of the Day is chosen by screening for stocks under $5 and then applying technical analysis on the shortlisted set of penny stocks showing unusual volume. When making these trades, please make sure to pay vigilant attention to pricing moves and have a strict stop loss in place to avoid significant losses.

Penny Stock of the Day: Adverum Biotechnologies Inc. (NASDAQ: ADVM)

Today’s penny stock pick is the clinical stage gene therapy company, Adverum Biotechnologies Inc. (NASDAQ: ADVM).

Adverum Biotechnologies Inc. develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration and diabetic macular edema. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; Cornell University; GenSight; Lexeo; and Virovek.

Website:  https://www.adverum.com

Latest 10-k report:  https://sec.report/Document/0001628280-22-007698

Analyst Consensus: As per TipRanks Analytics, based on 3 Wall Street analysts offering 12-month price targets for ADVM in the last 3 months, the stock has an average price target of $6.00, which is nearly 329% upside from current levels.

Source: TipRanks.com

Analysts | Source: TipRanks.com

Potential Catalysts / Reasons for the Hype:

  • Rumors of an imminent buyout.
  • Corporate Insiders Bought Shares Worth $119.9K in the Last 3 Months.

    Insiders | Source: TipRanks.com

  • The European Medicines Agency (EMA) granted Adverum’s lead gene therapy candidate, ADVM-022 Priority Medicines (PRIME) designation for the treatment of wet age-related macular degeneration (wet AMD).

On analyzing the company’s stock charts, there seem to be multiple bullish indications…

Bullish Indications

#1 Downtrend Channel Breakout: The daily chart shows that the stock has broken out of a downtrend channel, which is shown as purple color lines. This is a possible bullish indication.

ADVM – Daily Chart

#2 Bullish ADX and DI: The ADX indicator shows bullishness as the +DI line is above the -DI line, and the ADX line is currently moving higher from below the +DI and -DI lines.

#3 Price above MA: The stock is currently above its 50-day SMA, indicating that the bulls have currently gained control.

#4 MACD above Signal Line: In the daily chart, the MACD (light blue color) is currently above the MACD signal line (orange color). This indicates a possible bullish setup.

#5 Bullish Aroon: The value of Aroon Up (orange line) is above 70 while Aroon Down (blue line) is below 30. This indicates bullishness.

#6 Above Support Area: The weekly chart shows that the stock is currently trading above a support area, which is marked as a pink color dotted line. This is a possible bullish indication.

ADVM – Weekly Chart

#7 Bullish Stoch: The %K line is above the %D line of the stochastic in the weekly chart as well, indicating possible bullishness.

#8 MACD above Signal Line: In the weekly chart, the MACD (light blue color) is currently above the MACD signal line (orange color). This indicates a possible bullish setup.

Recommended Trade (based on the charts)

Buy Levels: If you want to get in on this trade, the ideal buy level for ADVM is above the price of $1.45.

Target Prices: Our first target is $1.90. If it closes above that level, the second target price is $2.30.

Stop Loss: To limit risk, place a stop loss at $1.20. Note that the stop loss is on a closing basis.

Our target potential upside is 31% to 59%.

For a risk of $0.25, our first target reward is $0.45, and the second target reward is $0.85. This is a nearly 1:2 and 1:3 risk-reward trade.

In other words, this trade offers 2x to 3x more potential upside than downside.

Potential Risks / Red Flags:

  1. The company has experienced net losses since its inception and has an accumulated deficit of $648.1 million as of December 31, 2021.

    ADVM – Consolidated Statements of Operations and Comprehensive Loss

  2. The company was formerly known as Avalanche Biotechnologies.
  3. Despite being a loss-making company, the executives are being paid millions as compensation.

    ADVM – Executive Compensation

As you can see, today’s featured penny stock offers big upside potential… but it also comes with a number of risks and red flags. As always, when dealing with penny stocks, we advise caution before entering into such high-risk ventures. Remember to think before you trade… understand the risks… and if you decide to trade, stick to your stop-losses!

Happy Trading!

— Trades of the Day Research Team

READ BEFORE TRADING PENNY STOCKS: The allure of penny stocks lies in their potential to deliver massive gains in a short period of time. However, in exchange for that opportunity, most penny stocks carry tremendous risk. They can be extremely volatile and are susceptible to “pump and dump” schemes and fraud.

Unlike regular stocks, the financial condition of most penny stock companies can be extremely difficult to analyze, as the majority of such stocks are traded on over-the-counter (OTC) exchanges, which are typically less transparent and less regulated than the major exchanges. In fact, in the penny stock space, it’s often easier to spot warning signs and red flags than it is to identify a sound investment. Nevertheless, we do our best to identify short-term trade opportunities in this exciting space because we know some of our readers are looking for high-risk, high-reward ideas. We just urge you to make sure you fully understand the risks before making any of these trades.

V-Tolling Is Set to Be More Popular than Electric and Self-Driving Cars COMBINED [sponsor]
You can be among the first early adopters of this new technology... and get in on the ground floor of ONE company trading for just $10 right now. Matt McCall breaks the full story and details his No. 1 recommendation, right here.